Guidance
10 Sources of evidence considered by the Committee
The diagnostics assessment report was prepared by Warwick Evidence.
-
Freeman K, Connock M, Auguste P, et al. Clinical and cost‑effectiveness of use of therapeutic monitoring of TNFα inhibitors (LISA‑TRACKER ELISA kits, Immundiagnostik TNFα‑Blocker ELISA kits, and Promonitor ELISA kits) versus standard care in people with Crohn's disease: systematic reviews and economic modelling. April 2015.
Registered stakeholders
The following organisations accepted the invitation to participate in this assessment as registered stakeholders. They were invited to attend the scoping workshop and to comment on the diagnostics assessment report and the diagnostics consultation document.
Manufacturers/sponsors:
-
Alpha Laboratories
-
Biohit Healthcare
-
Immundiagnostik AG
-
Proteomika SLU
Professional/specialist and patient/carer groups:
-
British Society of Gastroenterology
-
British Society of Paediatric Gastroenterology, Hepatology and Nutrition
-
Crohn's and Colitis UK
-
Pelvic Pain Support Network
-
Royal College of Nursing
-
Royal College of Pathologists
-
Royal College of Physicians
-
UK Clinical Pharmacy Association (UKCPA)
Others:
-
AbbVie Ltd
-
Euro Diagnostica AB
-
Matriks Biotek
-
Merck Sharp & Dohme
-
Viapath
-
Department of Health
-
Healthcare Improvement Scotland
-
NHS England
-
Royal Devon and Exeter Foundation NHS Trust
-
Sandwell and West Birmingham Hospitals NHS Trust
-
Welsh Government
ISBN: 978-1-4731-1686-3